Abstract
Stevens–Johnson syndrome and the related disease toxic epidermal necrolysis are life-threatening reactions of the skin to particular types of medication1,2,3. Here we show that there is a strong association in Han Chinese between a genetic marker, the human leukocyte antigen HLA–B*1502, and Stevens–Johnson syndrome induced by carbamazepine, a drug commonly prescribed for the treatment of seizures. It should be possible to exploit this association in a highly reliable test to predict severe adverse reaction, as well as for investigation of the pathogenesis of Stevens–Johnson syndrome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Roujeau, J.-C. J. Invest. Dermatol. 102 (suppl.), 28–30 (1994).
Roujeau, J.-C. et al. N. Engl. J. Med. 333, 1600–1607 (1995).
Rzany, B. et al. Lancet 353, 2190–2194 (1999).
Svensson, C. K., Cowen, E. W. & Gaspari, A. A. Pharmacol. Rev. 53, 357–379 (2001).
Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. Nature Rev. Genet. 4, 937–947 (2003).
Roujeau, J. -C. et al. Tissue Antigens 28, 251–254 (1986).
Erlich, H. A., Opelz, G. & Hansen, J. Immunity 14, 347–356 (2001).
Khoo, A. K. M. & Foo, C. L. Burns 22, 275–278 (1996).
Kamaliah, M. D., Zainal, D., Mokhtar, N. & Nazmi, N. Int. J. Dermatol. 37, 520–523 (1998).
Geer, L., Terasaki, P. I. & Gjertson, D. W. in HLA 1998 (eds Gjertson, D. W. & Terasaki, P. I.) 327–363 (Am. Soc. Histocompat. Immunogenet., Kansas, 1998).
Schlosstein, L., Terasaki, P. I., Bluestone, R. & Pearson, C. M. N. Engl. J. Med. 288, 704–706 (1973).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table S1 and S2
Supplementary Table S1: Clinical data of patients with carbamazepine-induced Stevens-Johnson syndrome; Supplementary Table S2: Demographic variables, dosage and duration of carbamazepine (CBZ) exposure in CBZ-induced Stevens-Johnson syndrome (SJS) and CBZ tolerant patients as well as normal subjects. (DOC 34 kb)
Supplementary Methods
Presents the procedure for patients and control subjects recruitment, criteria for phenotype definition, PCR primers sequences for HLA-B allele typing, and statistical analysis. (DOC 24 kb)
Rights and permissions
About this article
Cite this article
Chung, WH., Hung, SI., Hong, HS. et al. A marker for Stevens–Johnson syndrome. Nature 428, 486 (2004). https://doi.org/10.1038/428486a
Published:
Issue Date:
DOI: https://doi.org/10.1038/428486a
This article is cited by
-
Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics
European Journal of Clinical Pharmacology (2024)
-
Genetics of bipolar disorder: insights into its complex architecture and biology from common and rare variants
Journal of Human Genetics (2023)
-
Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics
Journal of Human Genetics (2023)
-
Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01
Scientific Reports (2023)
-
Black-Box Warnings of Antiseizure Medications: What is Inside the Box?
Pharmaceutical Medicine (2023)